Survivin is a member of the inhibitor of apoptosis protein (IAP) family and functions both as an apoptosis inhibitor and a regulator of cell division. Survivin overexpression is common in many human tumors and correlates with survival in large cell non-Hodgkin's lymphoma. To evaluate this molecule as a potential therapeutic target in large-cell lymphoma, we evaluated the effect of survivin inhibition both in vitro and in vivo. Using an antisense oligonucleotide (ASO) approach, cell growth was significantly inhibited in the DoHH2, RL and HT lymphoma cell lines. In a lymphoma xenograft model, the development of tumors as well as the growth of established tumors was inhibited in the survivin ASO-treated mice compared to controls. To assess the efficacy of the survivin ASO in combination with other biological agents, we combined the survivin ASO with an anti-CD20 monoclonal antibody, rituximab. The effect of survivin ASO and rituximab in combination was additive in vitro. In vivo, however, suppression of tumor growth with the combination was not significantly superior to controls. We conclude that inhibition of survivin expression is an attractive therapeutic strategy in aggressive non-Hodgkin's lymphomas, and that combining survivin ASO with rituximab may enhance the efficacy of this approach.
Introduction
The inhibition of apoptosis and increased proliferation are important mechanisms involved in cancer formation. By extending the lifespan of cells and increasing the frequency of cell division, they favor the accumulation of transforming mutations. Studies in non-Hodgkin's lymphoma have suggested that these mechanisms are important in lymphoma cells and that these cells are commonly resistant to apoptosis and have an increased proliferative index. [1] [2] [3] Apoptosis pathways are effectively blocked by proteins belonging to the inhibitor of apoptosis protein (IAP) family, which directly inhibit caspase and procaspase molecules. Recently, survivin has been cloned and characterized as an important member of the IAP family. It is located on chromosome 17q25 4 and functions as both an apoptosis inhibitor and a regulator of cell division. 5 Survivin is expressed during the mitotic phase of the cell cycle and localizes to multiple components of the mitotic apparatus and centrosome. 6, 7 Survivin overexpression has been shown to counteract apoptosis in vitro and also in transgenic animals. 6 In addition, the use of antisense molecules to downregulate survivin expression 8 or homozygous deletion of survivin in mice 9 results in a catastrophic defect of mitosis with multipolar spindles and aberrant tubulin assembly.
In contrast to other IAPs, survivin is expressed predominantly during fetal development and in proliferating cells and is low or absent in normal differentiated tissues. However, it is abundantly expressed in a wide variety of human malignancies, including melanoma, bladder, lung, breast, hematopoietic, neuroblastoma, prostate, gastric, and pancreatic cancers. 4, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] The expression of survivin appears to correlate with aggressive tumor behavior and poor prognosis in colorectal cancers, 16, 22, 23 neuroblastomas, 15 melanomas, 24 non-small-cell lung cancers, 18 breast carcinomas, 21 de novo acute myeloid leukemia, 25 and esophageal squamous cell carcinomas. 26 Additionally, survivin overexpression is also considered a risk factor for resistance to chemotherapy and radiation treatment. 13, 27 A recent study has also shown that survivin is overexpressed in diffuse large B-cell lymphoma and this is a negative prognostic factor for survival in these patients. 11 The role of survivin expression in lymphomas, however, is largely unknown, and to our knowledge it has not been determined whether the survivin pathway may be exploited in human largecell lymphoma to induce apoptosis and arrest malignant cell growth. The only study evaluating survivin inhibition in lymphoma published to date utilized plasmids encoding antisense survivin in combination with the development of antitumor cytotoxic T-lymphocytes in murine lymphoma cells. 28 This study was therefore conducted to determine whether survivin inhibition in human lymphoma cells, by the administration of an antisense oligonucleotide (ASO), would significantly inhibit their growth both in vitro and in lymphoma xenografts. A further aim of the study was to determine whether the effect of survivin inhibition on lymphoma cells would be additive when combined with other biologic therapies that target malignant B cells, such as the anti-CD20 monoclonal antibody rituximab.
Materials and methods

Cells and cell culture
RL and HT cell lines were obtained from American Type Culture Collection (ATCC) and the DoHH2 cells were a gift from Dr A Fielding. RL is a mature EBV negative, CD20 þ , B-cell line derived from a diffuse large-cell lymphoma and carries a chromosomal marker t(14;18)(q32;q21). HT is also an EBVnegative, CD20 þ , B-cell line derived from a diffuse mixed small-and large-cell lymphoma. These cells do not have the t(14;18) marker but do have a t(3;11) translocation. DoHH2 is an EBV-negative, CD20 positive, human B-cell non-Hodgkin's lymphoma cell line that carries the t(14;18)(q32;q21) and was isolated from a patient with a transformed lymphoma. RL and HT cells were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated FCS (Sigma Chemical Co.), 50 U/ml penicillin G, 50 mg/ml gentamicin and 100 mg/ml streptomycin (all from Life Technologies, Grand Island, NY, USA). DoHH2 cells were maintained in the same media with the addition of 10 mM HEPES, 4.5 g/l glucose and 1 mM sodium pyruvate.
Antisense oligonucleotides
ISIS 23722 (5 0 -TGTGCTATTCTGTGAATT) is an antisense oligonucleotide (ASO) that significantly inhibits survivin expression, 8 and was provided for this study by ISIS pharmaceuticals (Carlbad, CA, USA). A scrambled control oligonucleotide, ISIS 28598 (5 0 -TAAGCTGTTCTATGTGTT), was used as a control. On the day of transfection, cells were washed once in serumfree Opti-MEM (Life Technologies Inc., Rockville, MD, USA) before resuspending at a concentration of 10 Â 10 6 cells/400 ml. In total, 400 ml of cells were incubated in a 0.4 cm electroporation cuvette (BTX Genetronics, San Diego, CA, USA) with 40 mg of survivin ASO or the control scrambled oligonucleotide or no ASO for 10 min at room temperature. The cells were pulsed once for 20 ms at 275 V using a square-wave electroporator (BTX Genetronics) and incubated at room temperature for 20 min prior to transfer to six-well plates (Becton Dickinson, Franklin Lakes, NJ, USA) containing media supplemented with FCS.
Animals
Male CB17/SCID mice (Harlan Sprague Dawley, Indianapolis, IN, USA), 6-8 weeks old, maintained in a pathogen-free environment, were used for all studies and were cared for according to the standards set by Mayo Foundation Institutional Animal Care and Use Committee (IACUC). The experimental protocol was reviewed and approved by the Mayo Foundation IACUC. Animals were assessed daily for illness by nonbiased technicians and terminated at signs of illness including, but not limited to, paralysis in the hind region, scruffy coat, lethargy, or weight loss of 420%. Mice whose tumor reached a volume of 2.5 cm 3 or began to invade surrounding tissue were euthanized.
Tumorigenicity experiments and the treatment of established tumors
To determine whether survivin inhibition could inhibit tumor development, DoHH2 cells were transfected with survivin ASO or a control scrambled oligonucleotide or no ASO and 1 Â 10 7 viable DoHH2 cells were injected subcutaneously into the flank region of each animal. The tumor growth was monitored daily in two dimensions and tumor size was calculated according to the formula v ¼ a 2 b/2, where a ¼ shortest and b ¼ longest diameter. There were five mice in each of the survivin antisense, contol oligonucleotide, and PBS control groups. DoHH2 cells were used for this and all subsequent animal studies due to the fact that the injected DoHH2 cells were more tumorigenic than the RL and HT cells. Injected DoHH2 cells generally formed a discrete mass at the injection site rather than disseminating in the animal, which made measuring the subsequent tumor growth more reliable.
To then determine the effect of survivin inhibition on established tumors, viable DoHH2 cells (1 Â 10 7 cells in 150 ml) were injected subcutaneously into the flank of each animal and allowed to develop measurable tumors. Cohorts of 10 animals were then treated in the following groups: (a) untreated control (injected with PBS); (b) animals treated with a control oligonucleotide (ISIS 28598) at a concentration of 25 mg/kg three times per week for 10 doses; and (c) animals treated with a survivin ASO (ISIS 23722) at a concentration of 25 mg/kg three times per week for 10 doses. To determine the effect of survivin inhibition in combination with rituximab therapy, viable DoHH2 cells (1 Â 10 7 cells in 150 ml) were injected subcutaneously into the flank of each animal and allowed to develop measurable tumors. Cohorts of five animals were then treated in the following groups: (a) untreated control (injected with PBS); (b) animals treated with survivin ASO (ISIS 23722) alone at a concentration of 25 mg/kg three times per week for 10 doses; (c) animals treated with rituximab alone at a dose of 25 mg/kg once per week for 3 weeks; (d) animals treated with both survivin ASO and rituximab at the above-mentioned doses; and (e) animals treated with a control oligonucleotide (ISIS 28598) at a concentration of 25 mg/kg three times per week for 10 doses in combination with rituximab at the above doses.
Immunoblotting
At 4 days following tumor cell injection, cell lysates were prepared using lysis buffer containing 50 mM Tris, pH 7.4; 150 mM NaCl; 1% NP-40; 0.5% sodium deoxycholate; 0.1% SDS 1 mM EDTA; 15 mM sodium molybdate; 1 mM NaF; 1 mM PMSF, 8 mg/ml leupeptin; 8 mg/ml aprotinin; 8 mg/ml pepstatin; 2 mM Na 3 VO 4 for 45 min on ice. The lysates were cleared of insoluble material by centrifugation for 10 min at 14 000 r.p.m. Cell lysates containing 50-75 mg of total protein were resolved by electrophoresis through 15% SDS-polyacrylamide gels and then transferred onto Immobilon-P membranes (Millipore, Bedford, MA, USA). The membranes were blocked in 25 mM Tris-HCl (pH 7.2), 150 mM NaCl and 0.05% Tween-20 supplemented with 5% milk and were probed with mouse anti-human survivin, clone 60.11 (Novus Biologicals, Inc., Littleton, CO, USA). Immunoreactive proteins were detected using an enhanced chemiluminescence detection system (Amersham, Arlington Heights, IL, USA).
Cell proliferation assays
Cells were transfected and cultured overnight in media supplemented with 10% FCS at a density of 10 Â 10 6 /ml in a six-well plate (Becton Dickinson, Franklin Lakes, NJ, USA) with a final volume of 5 ml. The cells were then washed, resuspended in media and cultured in 96-well, flat-bottom microtiter plates (Costar, Cambridge, MA, USA) at a density of 2.5 Â 10 4 cells/ well in a final volume 200 ml. Cells were incubated for 3 days at 371C in the presence of 5% CO 2 . To measure DNA synthesis, 1 mCi of [ 
Caspase-3 activity assay
Lymphoma cell lines were transfected, cultured for 24-72 h, washed and plated into a 96-well plate (5 Â 10 6 cells/well in 25 ml of phenol-free RPMI in triplicate). As a control, wells were incubated with the caspase-3 specific inhibitor Ac-DEVD-CHO (50 nM final) (BIOMOL, Plymouth Meeting, PA, USA) for 30 min at 371C prior to addition of 50 ml of the caspase-3 specific fluorogenic substrate Ac-DEVD-AMC (33 mM final) (BIOMOL) in substrate buffer. Cleavage of the caspase-3 specific substrate was assessed by fluorescence using a CytoFluor Multi-well Plate Reader (Applied Biosystems, Foster City, CA, USA).
Analysis of DNA content
For cell cycle analysis, 2 Â 10 6 DoHH2 cells transfected with scrambled or survivin ASO or a PBS control and were cultured for 24 or 96 h. Cells were pelleted and permeabilized for 30 min in 2.0 ml Dulbecco's PBS (Gibco) containing 1% paraformaldehyde with 0.02 mg of lysophosphatidylcholine (Sigma Chemical Co.). Following permeabilization, RNA was degraded during a 30 min incubation at 371C in DPBS containing 0.1 mg/ml Rnase A (Sigma Chemical Co.). Before fluorescence analysis, 0.05 mg/ ml propidium iodide (Sigma Chemical Co.) was added to the cells and DNA was allowed to stain for 30 min at 41C. Propidium iodide analysis for DNA content was performed on a FACScan (Becton Dickinson, Mountain View, CA, USA). Data were analyzed using the WinMDI program (Becton Dickinson).
Statistical analysis
The Fisher exact test was used to compare differences in nominal variables, while the rank-sum test or the Kruskal-Wallis test was used for continuous variables. In the animal studies, survival duration was determined from the day of tumor injection to the day the animals were killed due to large tumor size. The overall survival of the mice was estimated using the Kaplan-Meier method and univariate associations were determined using the log-rank test. All statistical tests were two-sided and Po0.05 was considered significant. Analysis was performed on Statview software (SAS Institute Inc, Cary, NC, USA).
Results
Downregulation of survivin inhibits lymphoma cell growth
To determine the effect of survivin inhibition on lymphoma cells, we used DoHH2, RL and HT cell lines as models of largecell lymphoma. The DoHH2, RL and HT cell lines showed high levels of survivin expression by Western blot analysis (Figure 1 ). To downregulate survivin expression, we utilized an ASO approach. Using the DoHH2, RL and HT lymphoma cell lines, we evaluated the effect of inhibition of survivin using an ASO to survivin (ISIS 23722), a control oligonucleotide (ISIS 28598) or no oligonucleotide (PBS control). By Western blot analysis, we showed that the survivin ASO significantly decreased the high level of survivin expression seen in these cells.
The decreased expression of survivin significantly inhibited cell proliferation as determined by [ 3 H]TdR incorporation in all three lymphoma cell lines (Figure 2a) . The decrease in proliferation was statistically significant when compared to cells treated with a control oligonucleotide or a PBS control for the RL (P ¼ 0.002 and Po0.001), the HT ((Po0.001 and P ¼ 0.001) and the DoHH2 cell lines (P ¼ 0.002 and P ¼ 0.006 respectively). When the absolute number of cultured DoHH2 and HT cells/ml was determined (Figure 2b -results with DoHH2 cells shown), exposure to the survivin ASO arrested the increase in absolute cell number. The number of RL cells treated with the survivin ASO originally increased over the first 48 h, but a further increase in cell number was minimal over the subsequent 5 days (data not shown). In contrast, the proliferation and increase in absolute cell number of both DoHH2 cells and RL cells was unchanged in the PBS and control oligonucleotide-treated cells.
Inhibition of survivin by means of the ASO also increased apoptosis in the lymphoma cell lines as measured by an increase in caspase-3 activity in the RL, HT, and DoHH2 cells (Figure 3a) . The level of caspase-3 activity significantly increased in the RL cell line 24 h after exposure to the survivin ASO, while there was no change in caspase-3 activity in the control cells (Po0.001) or after exposure to a control oligonucleotide (Po0.001). The same finding was true of the HT (P ¼ 0.006 and P ¼ 0.003) and the DoHH2 cell line (Po0.001 and Po0.001 respectively). Interestingly, the HT cells had a high background level of caspase activity despite having high levels of survivin expression. However, there was a further substantial increase in caspase-3 activity after inhibition of survivin using the survivin ASO. The percent viable cells in serum-free culture over time was determined by flow cytometry using annexin V and propidium iodide (Figure 3b ). After electroporation, the percent viable cells decreased for all experimental groups. However, significantly fewer cells exposed to the survivin ASO remained viable over a 15-day period compared to cells treated with the control oligonucleotide (P ¼ 0.014) or no oligonucleotide (P ¼ 0.008).
Similar to previous reports in nonhematologic malignancies, Survivin antisense oligonucleotide significantly decreases survivin expression in RL, HT and DoHH2 lymphoma cell lines. Day 3 postelectroporation, a Western blot on whole-cell lysates from the RL, HT and DoHH2 lymphoma cell lines was performed using a monoclonal anti-survivin antibody (Novus Biologicals, Littleton, CO, USA). The effect of the survivin antisense oligonucleotide on survivin expression was compared to the effects of a scrambled control oligonucleotide and no oligonucleotide (PBS control). MAP kinase was used as a control.
Survivin inhibition in large-cell lymphoma SM Ansell et al undergoing a mock transfection had normal morphology and ploidy. Similar results were seen with the RL and HT cell lines.
Effects of survivin inhibition on lymphoma cell growth in SCID mice
To determine the relevance of these findings in vivo, we examined tumorigenicity of the DoHH2 cells in immunodeficient mice after treatment with survivin ASO. First, we determined whether transfection of the DoHH2 cells with the survivin antisense prior to injection into the SCID mice would inhibit the cell growth and prevent or delay tumor development. DoHH2 lymphoma cells were electroporated in the presence of the survivin antisense oligonucleotide, a control oligonucleotide or underwent a mock transfection (no oligonucleotide). The cells were then injected into the flank of the mice and the mice were monitored for the onset and rate of tumor growth. There were five mice per group. When compared to controls, the survivin antisense oligonucleotide significantly inhibited the growth of DoHH2 lymphoma cells in SCID mice (P ¼ 0.003) and delayed tumor development in the mice (Figure 4a ). We then used survivin ASO to treat established lymphoma xenografts by direct intratumoral injection. DoHH2 lymphoma cells were injected into SCID mice and allowed to form established tumors over a 4-week period. The survivin ASO, a control oligonucleotide, or no oligonucleotide (PBS control) was then administered by direct local injection into the tumor at a concentration of 25 mg/kg three times per week for 10 doses. There were 10 mice per group. The survivin ASO was found to suppress the growth of the tumors (Figure 4b) , and when compared to animals receiving the control oligonucleotide (P ¼ 0.05) or PBS (P ¼ 0.01), survivin antisense-treated animals had a superior survival (Figure 4c ). Tumors removed from the survivin antisense-treated mice showed downregulation of survivin expression by Western blot analysis (Figure 4d ).
Survivin inhibition in combination with rituximab
Using DoHH2 cells, the effect of the survivin ASO administered in combination with the anti-CD20 antibody, rituximab, was determined. The percent viable cells in serum-free culture over time was determined by flow cytometry using annexin V and propidium iodide (Figure 5a ). After electroporation, the percent viable cells decreased for all experimental groups. However, significantly fewer cells exposed to the survivin ASO in combination with rituximab remained viable over a 9-day period compared to cells treated with the survivin ASO (P ¼ 0.03) or rituximab alone (P ¼ 0.04).
DoHH2 lymphoma cells were then injected into SCID mice and palpable tumors were allowed to develop. The animals were treated intratumorally in the following groups: (a) untreated control (injected with PBS); (b) animals treated with Inhibition of DoHH2 cell growth by survivin antisense oligonucleotide in SCID mice. (a) DoHH2 lymphoma cells were electroporated in the presence of survivin antisense, a control oligonucleotide or no oligonucleotide and injected into SCID mice. There were five mice per group. The results are reported as the mean7standard error. (b) DoHH2 lymphoma cells then were injected into the mice and allowed to form established tumors. The survivin antisense oligonucleotide, a control oligonucleotide, or no oligonucleotide (PBS control) was administered by direct local injection into the tumor once a measurable tumor was present. The oligonucleotides were suspended in PBS and administered at a concentration of 25 mg/kg three times per week for 10 doses. There were 10 mice per group. The results are reported as the mean7standard error. (c) The survival time of animals treated with survivin ASO was determined by the Kaplan-Meier method and found to be significantly better than control animals. Day 0 represents the day the intratumoral injections were started. (d) Survivin expression, by Western blot analysis was determined in the tumors taken from these mice. MAP kinase was used as a control. Owing to the size of the gels used, cell lysates were randomly obtained from seven mice from each cohort and showed a decrease in survivin expression in the mice treated with the survivin ASO.
survivin ASO (ISIS 23722) alone at a concentration of 25 mg/kg three times per week for 10 doses; (c) animals treated with rituximab alone at a dose of 25 mg/kg once per week for 3 weeks; (d) animals treated with both survivin ASO and rituximab at the above-mentioned doses; and (e) animals treated with a control oligonucleotide (ISIS 28598) at a concentration of 25 mg/kg three times per week for 10 doses in combination with rituximab at the above doses. There were 10 mice per group. Tumor growth was suppressed in animals receiving the combination of survivin ASO and rituximab (Figure 5b ) when compared to control cohorts (P ¼ 0.05); however, there was no significant difference in the survival of mice receiving the combination when compared to the other control groups (P ¼ 0.26).
Discussion
The IAP family is known to include several important antiapoptotic family members, including survivin, IAP1, and XIAP, among others. These proteins are thought to be direct inhibitors of effector caspases and may, indeed, act additionally downstream to inhibit apoptosis. Unique among IAP proteins, survivin is only normally expressed during embryonic and fetal development and is not present in differentiated adult tissues. It is now clear that survivin expression is common in many human tumors and has important prognostic significance. 4, 10, [13] [14] [15] [16] [17] [18] [19] [20] [21] An increased level of survivin expression has been reported in the malignant lymphocytes from patients with large-cell nonHodgkin's lymphoma and was found to be associated with a poor clinical outcome. 11 This would suggest that survivin may be an important molecule in aggressive lymphomas and may be a potential therapeutic target in this disease. To test this hypothesis, we evaluated the effect of survivin inhibition both in vitro and in vivo, and also combined this strategy with the use of a monoclonal antibody targeting CD20 on the malignant B cells.
Using an antisense oligonucleotide against survivin, we have shown that survivin expression in lymphoma cells can be significantly downregulated when compared to controls. This downregulation of survivin expression inhibited proliferation of lymphoma cells and also increased apoptosis. Furthermore, an increase in the number of lymphoma cells in culture was inhibited for at least 7 days and a decrease in the percentage of viable cells over a 15-day period was seen after exposure to the survivin ASO. As previously published 8 in other cell types, we found that the survivin ASO caused profound pleomorphic changes in the lymphoma cells within three days that was associated with a mitotic block which the cells seemed unable to overcome (data not shown).
It could be argued that these effects on the cells are due to nonspecific inhibition of other molecules by the antisense oligonucleotide. Owing to the fact that the coding strand of the survivin gene is highly similar to the sequence of effector cell protease receptor-1 (EPR-1), 4 it is possible that EPR-1 is actually being inhibited rather than survivin. The role of EPR-1 appears to be that of a receptor for factor Xa that induces endothelial cell activation. 29 A recent study, however, failed to detect transcripts in the human or murine genome that correspond to the published sequence of EPR-1 suggesting that EPR-1 is either highly cell-specific or that the published EPR-1 cDNA includes sequences from clones derived from survivin messenger RNA. 30 Furthermore, the pleomorphic changes, inhibition of proliferation and increase in apoptosis seen in survivin antisense-treated cells would suggest that survivin is specifically being inhibited.
We have also shown that use of the survivin ASO inhibits the growth of lymphoma cells in vivo. We chose to use DoHH2 cells in this SCID mouse model because the animals injected with these cells form localized tumors rather than disseminated disease, making measurement of developing tumors more reliable. Furthermore, DoHH2 cells have also successfully been used in other animal models evaluating antisense molecules. In this study, DoHH2 cells exposed to the survivin ASO prior to injection into SCID mice, took significantly longer to develop a tumor mass when compared to cells exposed to a control oligonucleotide or PBS. The growth of large, established tumors Inhibition of DoHH2 lymphoma cells in vitro and in vivo after treatment with survivin antisense oligonucleotide in combination with rituximab, an anti-CD20 antibody. (a) The percent viable DoHH2 cells in culture in serum free conditions over a 9-day period was determined by annexin V and propidium iodide flow cytometric analysis. Significantly fewer viable cells at day 9 were present after treatment with survivin ASO in combination with rituximab than in the control groups. (b) DoHH2 lymphoma cells then were injected into the mice and allowed to form established tumors. Survivin antisense oligonucleotide, control oligonucleotide, rituximab or these agents in combination were administered by intratumoral injection once a measurable tumor was present. The oligonucleotides were suspended in PBS and administered at a concentration of 25 mg/ml three times per week for 10 doses. Rituximab was administered at a dose of 25 mg/ kg weekly for 3 weeks. There were five mice per group. The growth of tumors was measured and reported as the mean7standard error.
in SCID mice was also suppressed by regional injections of the survivin ASO when compared to controls. The oligonucleotide was effectively delivered to the cells, as confirmed by the decrease in survivin expression seen in the tumors obtained from the mice after treatment.
To further evaluate the role of survivin downregulation in the biologic therapy of B-cell lymphoma, we combined the survivin ASO with rituximab. Rituximab is a chimeric murine/human monoclonal antibody that binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35) located on pre-B and mature B-lymphocytes. 31, 32 While the Fab domain of rituximab binds to the CD20 antigen, the Fc domain recruits immune effector functions to mediate lysis of the B cell. 33 In vitro, rituximab induces apoptosis, 34, 35 complement-dependent cytotoxicity (CDC) 36, 37 and antibody-dependent cellular cytotoxicity (ADCC) 33, 36 in malignant B cell lines. Rituximab is commonly used in the treatment of patients with relapsed B-cell non-Hodgkin's lymphoma. [38] [39] [40] We found that the combination of these two agents decreased the fraction of viable cells after 9 days significantly more than either agent alone. When tested in the same lymphoma xenograft model, the combination of the survivin ASO and rituximab inhibited tumor growth more than the survivin ASO or rituximab alone, and to a greater degree than rituximab in combination with a control oligonucleotide. However, the combination of rituximab and survivin ASO did not prolong the survival of the animals when compared to controls in this model.
We therefore conclude that the inhibition of survivin significantly suppresses lymphoma cell growth both in vitro and in vivo, suggesting that survivin may be a promising therapeutic target in aggressive non-Hodgkin's lymphomas. Combining agents that inhibit survivin, such as survivin ASO, with other biologic therapies such as rituximab may further increase the efficacy of this strategy.
